Emera and Canadian Utilities have agreed to merge, creating a Canadian utility and energy infrastructure company valued at about $72 billion. This merger is the largest ever between two Canadian companies and will form a top 20 North American utility, operating under the Emera name with headquarters in Halifax. The combined company will serve around six million customers across Canada, the US, and international markets, with about 80% of earnings expected from Florida and Alberta. The deal includes an all-share arrangement and is expected to boost adjusted earnings per share in the first full year after closing, with a $32 billion capital plan through 2030 to support growth.
The Emera and Canadian Utilities merger is notable in the Canadian market. For readers following the Utilities sector, here is Pluang's market snapshot as of Oct 06, 2026 22:01 WIB: all 22 sampled US Utilities stocks rose today. Among them, American Electric Power Company Inc (AEP) led with a price of USD 120.90 and a 0.98% increase, followed closely by NextEra Energy, Inc. (NEE) at USD 77.01 with a 0.96% rise, and Sempra Energy (SRE) at USD 78.91 with a 0.95% gain. Typical hold times vary from 6 days for SRE to 83 days for NEE, while Pluang order activity shows a strong buy interest for AEP and SRE, contrasting with a more balanced buy-sell split for NEE.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
